Nurix Therapeutics (NASDAQ:NRIX) Insider Gwenn Hansen Sells 4,356 Shares of Stock

Nurix Therapeutics, Inc. (NASDAQ:NRIX) insider Gwenn Hansen sold 4,356 shares of the stock in a transaction dated Wednesday, August 5th. The shares were sold at an average price of $25.00, for a total transaction of $108,900.00. Following the completion of the sale, the insider owned 117,227 shares of the company’s stock, valued at $2,930,675. This trade represents a 3.58% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Gwenn Hansen also recently made the following trade(s):

• On Tuesday, August 4th, Gwenn Hansen sold 4,111 shares of Nurix Therapeutics stock. The stock was sold at an average price of $24.36, for a total transaction of $100,143.96.
• On Thursday, July 30th, Gwenn Hansen sold 3,847 shares of Nurix Therapeutics stock. The shares were sold at an average price of $23.38, for a total value of $89,942.86.
• On Thursday, June 25th, Gwenn Hansen sold 5,394 shares of Nurix Therapeutics stock. The shares were sold at an average price of $20.00, for a total value of $107,880.00.

Nurix Therapeutics Stock Up 1.7%

NASDAQ:NRIX opened at $25.12 on Thursday. The company has a market cap of $2.61 billion, a price-to-earnings ratio of -7.28 and a beta of 1.79. The company has a fifty day simple moving average of $20.95 and a two-hundred day simple moving average of $17.96. Nurix Therapeutics, Inc. has a 52 week low of $8.19 and a 52 week high of $25.40.

Nurix Therapeutics (NASDAQ:NRIX) last posted its quarterly earnings data on Thursday, July 9th. The company reported ($0.81) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.73) by ($0.08). The firm had revenue of $9.04 million during the quarter, compared to analysts’ expectations of $15.29 million. Nurix Therapeutics had a negative net margin of 928.44% and a negative return on equity of 76.09%. On average, analysts expect that Nurix Therapeutics, Inc. will post -2.84 EPS for the current year.

Analysts Set New Price Targets

Several analysts have recently weighed in on NRIX shares. Morgan Stanley raised their target price on Nurix Therapeutics from $36.00 to $38.00 and gave the company an “overweight” rating in a research note on Tuesday, July 28th. BTIG Research reaffirmed a “buy” rating and issued a $32.00 price objective on shares of Nurix Therapeutics in a report on Friday, July 10th. Royal Bank Of Canada raised their price target on shares of Nurix Therapeutics from $30.00 to $33.00 and gave the company an “outperform” rating in a research note on Friday, July 10th. Truist Financial lifted their price target on Nurix Therapeutics from $32.00 to $34.00 and gave the company a “buy” rating in a report on Friday, July 10th. Finally, UBS Group boosted their price objective on Nurix Therapeutics from $23.00 to $31.00 and gave the stock a “buy” rating in a research report on Wednesday, July 22nd. Thirteen research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, Nurix Therapeutics has an average rating of “Moderate Buy” and an average target price of $34.00.

Institutional Investors Weigh In On Nurix Therapeutics

A number of institutional investors have recently added to or reduced their stakes in NRIX. Vanguard Group Inc. boosted its stake in Nurix Therapeutics by 32.5% during the 4th quarter. Vanguard Group Inc. now owns 5,949,512 shares of the company’s stock valued at $112,862,000 after purchasing an additional 1,460,736 shares in the last quarter. General Atlantic L.P. bought a new stake in shares of Nurix Therapeutics in the 4th quarter worth $92,899,000. Morgan Stanley lifted its holdings in shares of Nurix Therapeutics by 115.9% in the fourth quarter. Morgan Stanley now owns 4,881,069 shares of the company’s stock valued at $92,594,000 after buying an additional 2,620,323 shares during the period. Vestal Point Capital LP lifted its holdings in shares of Nurix Therapeutics by 35.0% in the fourth quarter. Vestal Point Capital LP now owns 4,690,000 shares of the company’s stock valued at $88,969,000 after buying an additional 1,215,000 shares during the period. Finally, Baker BROS. Advisors LP boosted its stake in Nurix Therapeutics by 20.0% during the fourth quarter. Baker BROS. Advisors LP now owns 4,658,556 shares of the company’s stock valued at $88,373,000 after buying an additional 776,431 shares in the last quarter.

Trending Headlines about Nurix Therapeutics

Here are the key news stories impacting Nurix Therapeutics this week:

• Positive Sentiment: Nurix will receive a $10 million milestone payment after Sanofi initiated a Phase 1 trial of the oral STAT6 degrader SAR448272/NX-3911 for type 2 inflammatory diseases. The company has earned approximately $139 million from the Sanofi collaboration and remains eligible for about $453 million in additional milestones, plus potential royalties and a U.S. co-development option. Nurix Announces $10 Million Milestone Payment
• Positive Sentiment: The company enrolled the first patient in the registrational Phase 3 DAYBreak CLL-306 trial of bexobrutideg in relapsed or refractory chronic lymphocytic leukemia and small lymphocytic lymphoma. The study is designed to test whether bexobrutideg can outperform pirtobrutinib, a key step toward potential regulatory approval and commercialization. Nurix Announces Phase 3 DAYBreak CLL-306 Enrollment
• Positive Sentiment: Needham reaffirmed its Buy rating and maintained a $34 price target, implying substantial upside from the referenced share price. The endorsement reflects continued analyst confidence in Nurix’s pipeline and commercial potential. Needham Rating Update
• Negative Sentiment: Insiders reported additional sales: CFO Hans van Houte sold 4,761 shares for approximately $116,000, while Gwenn Hansen sold 8,467 shares across August 4–5 for roughly $209,000. The transactions were conducted under pre-arranged Rule 10b5-1 plans, reducing their significance as a bearish signal, but they still represent some near-term insider selling pressure.

Nurix Therapeutics Company Profile

Nurix Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of small-molecule therapies that harness the ubiquitin-proteasome system to selectively degrade disease-causing proteins. By modulating E3 ubiquitin ligases and related molecular machinery, Nurix aims to expand treatment options for patient populations with unmet medical needs in oncology and immunology.

The company’s pipeline includes multiple programs in various stages of development.